Drug Trial Radar · NCT04351685
Evaluation of Efficacy and Safety of VPM1002 in Comparison to BCG in Prevention of Tb Infection in Infants
Last checked: Nov 19, 2026Latest source record: Feb 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
6,940
Actual
Start
Nov 9, 2020
Primary completion
Oct 30, 2024
Study completion Oct 30, 2024
Sponsor
- Lead sponsor
- Serum Institute of India Pvt. Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Serum Life Science Europe GmbH
- First posted
- Apr 17, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 0 days, up to 14 days
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The trial is designed as a phase III, double-blind, multicenter, randomized, single administration, active-controlled, parallel-group design with two groups of newborn infants receiving either VPM1002 or BCG SII (1:1 allocation) to assess the efficacy, safety and immunogenicity of VPM1002 against Mtb infection.
Conditions
- Mycobacterium Tuberculosis Infection
Interventions
VPM1002Biological
The active ingredient of the recombinant BCG vaccine, VPM1002 is Mycobacterium bovis A dose of 0.05 ml will be administered intradermally. Manufactured by the Serum Institute of India Pvt. Ltd., India Diluent: 1 ml of Water for injection/vial
BCG SIIBiological
Commercially available BCG vaccine from Serum Institute of India Pvt. Ltd. A dose of 0.05 ml will be administered intradermally. Manufactured by the Serum Institute of India Pvt. Ltd., India Diluent: 1 ml of Sodium Chloride for injection/vial Injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incident cases of QFT conversion, indicating Mtb infectionTime frame: Minimum of 12 months and maximum of 36 months
Locations
12 sites in 5 countries. Site status is shown where the registry gives one.
Centre de Recherches Médicales de Lambaréné
Lambaréné, Gabon
Kenya Medical Research Institute / Center for Respiratory Disease Research
Nairobi, Kenya
Kenya Medical Research Institute - Center for Respiratory Disease Research
Siaya, Kenya
Family Center for Research with Ubuntu
Cape Town, South Africa
Mecru Clinical Research Unit
Medunsa, South Africa
Respiratory and Meningeal Pathogens Research Unit
Soweto, South Africa
South African Tuberculosis Vaccine Initiative
Worcester, South Africa
Empilweni Services and Research Unit (ESRU)
Johannesburg, Coronation Ville, South Africa
Ifakara Health Institute
Dar es Salaam, Tanzania
The national institute for Medical Research (NIMR) - Mbeya Medical Research Center (MMRC)
Mbeya, Mbeya, Tanzania
Medical Research Council / Uganda Virus Research Institute and London School of Hygiene and Tropical Medicines (MRC/UVRI and LSHTM) Uganda Research Unit
Entebbe, Uganda
Makerere University/CISMAC
Kampala, Uganda
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.